Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, and will now pause its development.
Inhibikase Therapeutics, Inc. (IKT), a biopharmaceutical company with a market capitalization of $189.48 million, has announced the halting of further development of its Parkinson's disease drug, ...
U.S. Department of Defense awards $4 million to researchers at OHSU, University of Washington, VA Portland, VA Puget Sound to ...
Stop the Spread. Injecting saline into mouse kidneys did not affect the left or right substantia nigra (top). Injecting fibrils of α-synuclein ablated about half of the dopaminergic neurons (middle ...
Mitochondria are critical for cellular homeostasis, regulating bioenergetics, redox balance, Ca2+ signaling, and cell death.
Hosted on MSN4d
Parkinson's disease could be treated by FDA-approved cancer drug after major research breakthroughA major research breakthrough on Parkinson's disease revealed that an already FDA-approved cancer drug could help stem the ...
The B vitamin mitigates manganese neurotoxicity, which produces symptoms that resemble Parkinson's disease. The vitamin improves dopamine production in the brain and offers potential therapeutic ...
Over time, the disease can also affect memory and lead to dementia. A similar condition called Lewy Body Dementia (LBD), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback